Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avenue Therapeutics Inc ATXI

Healthcare Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive... see more

Recent & Breaking News (NDAQ:ATXI)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

ACCESSWIRE IA October 28, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

ACCESSWIRE IA October 23, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

PR Newswire October 14, 2020

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

GlobeNewswire October 12, 2020

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

GlobeNewswire September 9, 2020

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2020

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

GlobeNewswire August 12, 2020

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

GlobeNewswire July 21, 2020

Fortress Biotech Added to Russell 3000® Index

GlobeNewswire June 29, 2020

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

GlobeNewswire June 5, 2020

Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders

GlobeNewswire May 29, 2020

Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire May 11, 2020

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

GlobeNewswire April 23, 2020

Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire March 30, 2020

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

GlobeNewswire February 13, 2020

Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

GlobeNewswire December 11, 2019

Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 4, 2019

Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

GlobeNewswire October 28, 2019

Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting

GlobeNewswire October 18, 2019

Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2019